Tumor-agnostic inhibitors in oncology: A new phase for precision medicine

Mu Chun Li, Hsing Pang Hsieh

研究成果: Article同行評審

1 引文 斯高帕斯(Scopus)

摘要

The study of precision medicine is flourishing in recent decades. Tumor-agnostic therapy is one of the targeted therapies, which can treat the malignant cells regardless of where they grow. Herein we reviewed currently the U.S. FDA-approved tumor-agnostic therapies: one monoclonal antibody as a PD-1 inhibitor called pembrolizumab and four small-molecule kinase inhibitors, larotrectinib, entrectinib, selpercatinib, and pralsetinib. We also summarized the reported synthetic routes toward three drugs and some developing candidates under clinical trials as tumor-agnostic therapy.

原文English
頁(從 - 到)2216-2224
頁數9
期刊Journal of the Chinese Chemical Society
67
發行號12
DOIs
出版狀態Published - 2020 十二月

All Science Journal Classification (ASJC) codes

  • 化學 (全部)

指紋

深入研究「Tumor-agnostic inhibitors in oncology: A new phase for precision medicine」主題。共同形成了獨特的指紋。

引用此